Literature DB >> 26527533

Model for end-stage liver disease excluding international normalized ratio (MELD-XI) score predicts heart transplant outcomes: Evidence from the registry of the United Network for Organ Sharing.

Salil V Deo1, Sadeer G Al-Kindi2, Salah E Altarabsheh3, Dustin Hang4, Sachin Kumar2, Mahazarin B Ginwalla2, Chantal A ElAmm2, Basar Sareyyupoglu5, Benjamin Medalion5, Guilherme H Oliveira2, Soon J Park5.   

Abstract

BACKGROUND: Hepato-renal function is a valuable predictor of success after left ventricular assist device therapy and heart transplantation. Hence, we analyzed the importance of the Model for End-stage Liver Disease excluding international normalized ratio (MELD-XI) score to outcomes after heart transplant.
METHODS: Adults undergoing heart transplant from the United Network for Organ Sharing (UNOS) database were identified (1994 to 2014). Individual MELD-XI scores were calculated; patients were stratified by MELD-XI quartiles (Q1 to Q4). Multivariate logistic regression and the Cox proportional hazard model were implemented to determine any association between MELD-XI scores, survival and other outcomes.
RESULTS: From 39,711 patients undergoing OHT during the study period, MELD-XI score [median 10.7 (interquartile range 7.0 to 14.4)] was calculated for 36,005 patients (76% male and 75% white, 34% Status 1A). Higher MELD-XI scores had higher rates of pre-transplant extracorporeal membrane oxygenation, intra-aortic balloon pump, inotrope use and mechanical ventilation (p < 0.001 for all). Adjusted long-term mortality (median follow-up 8.1 years) was associated with MELD-XI score (hazard ratio [HR] 1.021 [1.016 to 1.026], p < 0.001). The highest MELD-XI quartile was associated with an HR 1.364 [1.255 to 1.482] risk of mortality compared with Q1. MELD-XI score was also associated with increased post-transplant infections (adjusted HR Q4 vs Q1: 1.364 [1.153 to 1.614], p < 0.001), stroke (adjusted HR Q4 vs Q1: 1.410 [1.074 to 1.852], p = 0.013), dialysis (adjusted HR Q4 vs Q1: 3.982 [3.386 to 4.683], p < 0.001), rejection (adjusted HR Q4 vs Q1: 1.519 [1.286 to 1.795], p = 0.003) and prolonged hospitalization (adjusted HR Q4 vs Q1: 1.635 [1.429 to 1.871], p < 0.001).
CONCLUSION: Hepato-renal dysfunction, measured with MELD-XI score, predicts morbidity and mortality in patients undergoing orthotopic heart transplantation. Etiology of hepato-renal dysfunction should be sought and treated before heart transplantation.
Copyright © 2016 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MELD-XI; congestive heart failure; heart transplant; hepatic dysfunction; hepato-renal failure; left ventricular assist device

Mesh:

Year:  2015        PMID: 26527533     DOI: 10.1016/j.healun.2015.10.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  15 in total

Review 1.  Congestive hepatopathy: Differentiating congestion from fibrosis.

Authors:  Alexander Lemmer; Lisa VanWagner; Daniel Ganger
Journal:  Clin Liver Dis (Hoboken)       Date:  2018-01-02

2.  A Propensity-matched Survival Analysis: Do Simultaneous Liver-lung Transplant Recipients Need a Liver?

Authors:  Kyle Freischlag; Brian Ezekian; Paul M Schroder; Michael S Mulvihill; Morgan L Cox; Matthew G Hartwig; Stuart Knechtle
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

3.  Variables of importance in the Scientific Registry of Transplant Recipients database predictive of heart transplant waitlist mortality.

Authors:  Eileen M Hsich; Lucy Thuita; Dennis M McNamara; Joseph G Rogers; Maryam Valapour; Lee R Goldberg; Clyde W Yancy; Eugene H Blackstone; Hemant Ishwaran
Journal:  Am J Transplant       Date:  2019-02-13       Impact factor: 8.086

Review 4.  Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy.

Authors:  Alexander Lemmer; Lisa B VanWagner; Daniel Ganger
Journal:  Hepatology       Date:  2018-09-22       Impact factor: 17.425

5.  Increased serum Wisteria floribunda agglutinin positive Mac-2 binding protein (Mac-2 binding protein glycosylation isomer) in chronic heart failure: a pilot study.

Authors:  Atsushi Okada; Hideaki Kanzaki; Yasuhiro Hamatani; Seiji Takashio; Hiroyuki Takahama; Makoto Amaki; Takuya Hasegawa; Yasuo Sugano; Satoshi Yasuda; Toshihisa Anzai
Journal:  Heart Vessels       Date:  2017-11-02       Impact factor: 2.037

6.  Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF).

Authors:  Justin L Grodin; Dianne Gallup; Kevin J Anstrom; G Michael Felker; Horng H Chen; W H Wilson Tang
Journal:  Am J Cardiol       Date:  2017-03-29       Impact factor: 2.778

Review 7.  Heart transplantation for adults with congenital heart disease: current status and future prospects.

Authors:  Hikaru Matsuda; Hajime Ichikawa; Takayoshi Ueno; Yoshiki Sawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-04-24

Review 8.  From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?

Authors:  Anna Sessa; Manon Allaire; Pascal Lebray; Mourad Medmoun; Alberto Tiritilli; Pierre Iaria; Jean-François Cadranel
Journal:  JHEP Rep       Date:  2021-01-27

9.  Clinical profiles and risk factors for early and medium-term mortality following heart transplantation in a pediatric population: A single-center experience.

Authors:  Komarakshi R Balakrishnan; Kemundel Genny Suresh Rao; Ganapathy Krishnan Subramaniam; Murali Krishna Tanguturu; Ajay Arvind; Veena Ramanan; Jagdish Dhushyanthan; K Ramasubramanian; K Suresh Kumaran; Gunalan Sellamuthu; Mohan Rajam; Senthil Mettur; Pradeep Gnansekharan; Ravikumar Ratnagiri
Journal:  Ann Pediatr Cardiol       Date:  2021-01-16

Review 10.  THE USE OF MELD SCORE (MODEL FOR END-STAGE LIVER DISEASE) AND DERIVATIVES IN CARDIAC TRANSPLANTATION.

Authors:  Ana Claudia Oliveira de Moraes; Olival Cirilo Lucena da Fonseca-Neto
Journal:  Arq Bras Cir Dig       Date:  2018-07-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.